Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors, and beta-blockers: a cross-sectional study in England
Paul R Ward1, Peter R Noyce2, Antony S St Leger3
1School of Health and Related Research, University of Sheffield, England, UK; 2School of Pharmacy and Pharmaceutical Sciences, University of Manchester, England, UK; 3School of Epidemiology and Health Sciences, University of Manchester, England, UK
Aim: To explore the relationship between actual and expected general medical practitioner (GP) practice prescribing rates for statins, angiotensin converting enzyme (ACE) inhibitors, and beta-blockers.
Background: There is a growing body of literature highlighting inequities in GP practice prescribing rates for many drug therapies. The equity of prescribing is of central importance in the area of therapeutics since it explores the interface between those patients who should and those who actually do receive a drug therapy.
Setting: Four primary care trusts (PCTs 1–4) in the North West of England, including 132 GP practices.
Methods: Actual and expected prescribing rates for statins, beta-blockers, and ACE inhibitors were specifically developed for each GP practice.
Results: There were no statistically significant correlations between actual and expected prescribing rates in PCT2 and PCT3, although in PCT1 there were statistically significant correlations for statins (0.286, p < 0.05) and ACE inhibitors (0.381, p < 0.01). In PCT4, correlations were moderate to high for beta-blockers (0.693, p < 0.01), and moderate for statins (0.541, p < 0.05) and ACE inhibitors (0.585, p < 0.01). Scatterplots highlighted large variations between individual GP practices (both within and between PCTs) in terms of the relationship between actual and expected prescribing rates.
Conclusion: This paper highlights variability between PCTs and GP practices in terms of the relationship between actual and expected prescribing rates. The findings from this paper may further advance the suggestion of inequities in prescribing rates for coronary heart disease (CHD) drugs, and studies such as this may be repeated in different therapeutic areas, healthcare settings, and countries.
Keywords: prescribing rates, equity, coronary heart disease, statins, beta-blockers, ACE inhibitor
Readers of this article also read:
Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite
Takahiro Ueno, Hironori Tsuchiya, Maki Mizogami, Ko Takakura
Published Date: 13 November 2008
Minoru Yamaoka, Yusuke Ono, Masahiro Takahashi, Ryosuke Doto, et al.
Published Date: 14 April 2009
Eduardo Pimenta, Suzanne Oparil
Published Date: 19 May 2009
Nazem Bassil, Saad Alkaade, John E Morley
Published Date: 11 June 2009
The cognitive basis of diglossia in Arabic: Evidence from a repetition priming study within and between languages
Published Date: 2 September 2009
Iwen F Grigsby, Lan Pham, Louis M Mansky, et al
Published Date: 24 December 2009
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis
Kenneth P Johnson
Published Date: 12 April 2010
Perspectives on electronic medical records adoption: electronic medical records (EMR) in outcomes research
Dan Belletti, Christopher Zacker, C Daniel Mullins
Published Date: 30 April 2010
Margari F, Sicolo M, Spinelli L, Mastroianni F, Pastore A, Craig F, Petruzzelli MG
Published Date: 1 August 2012
Enriquez GG, Rizvi SAA, D’Souza MJ, Do DP
Published Date: 10 April 2013